Program for Drug Development in Leukemia

Program for Drug Development in Leukemia

Share
Share
Eytan Stein at a computer with nurse practitioner Bernadette Cuello

Eytan Stein (left) with nurse practitioner Bernadette Cuello. Dr. Stein directs the Program for Drug Development in Leukemia.

The Program for Drug Development in Leukemia (PDD-L) offers patients the most advanced treatments available for acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia through participation in phase 1 clinical trials.  Within this program, we concentrate on trials with novel therapeutics and new mechanisms of action coupled with translational research that support future scientific discoveries.

In the PDD-L our goal is to:

  • Improve the survival and quality of life of patients with leukemias and related diseases
  • Rapidly translate preclinical science into novel treatments for patients
  • Build an effective drug development program that excels in data collection, regulatory compliance, and rapid study activation. 

To make an appointment or refer a patient, please call 646-608-3749.

If you would like further information about the Program for Drug Development in Leukemia, please contact:

Eytan Stein, MD (Director)
[email protected]

PDDL Clinical Trial Team
[email protected]

Learn more

  • Our Team and Approach
    Learn about the mission and approach of the Program for Drug Development in Leukemia at Memorial Sloan Kettering Cancer Center.
  • Current Trial Portfolio
    Learn about the trials that are part of the Program for Drug Development in Leukemia at Memorial Sloan Kettering Cancer Center.
  • FAQs
    Questions and answers about the Program for Drug Development in Leukemia at Memorial Sloan Kettering Cancer Center.